2007
DOI: 10.1590/s0365-05962007000300002
|View full text |Cite
|
Sign up to set email alerts
|

Fatos e mitos sobre imunomoduladores

Abstract: Resumo: O objetivo deste artigo é discutir alguns fatos dos imunomoduladores modernos que podem ser úteis para o dermatologista clínico. Outro objetivo importante é o de dissipar mitos que possam ter impacto negativo no uso dessas drogas pelo clínico. O foco inicial está em imunomoduladores estimuladores que podem conduzir à acentuação da resposta normal das células imunocompetentes. Para tanto, diversos aspectos associados à regulação do sistema imune e às vias regulatórias das células do sistema imune são me… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
4
0
1

Year Published

2009
2009
2022
2022

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 80 publications
0
4
0
1
Order By: Relevance
“…Theoretically, if calibrated correctly to pharmacokinetic and pharmacodynamic equilibrium, these antagonists should allow immune system stability without causing major immunosuppression. 53 Adalimumab has been approved for the treatment of psoriatic arthritis and moderate to severe chronic psoriasis in dermatology. Case reports mention adalimumab in treating hidradenitis suppurativa, pyoderma gangrenosum, Sweet syndrome, Immunotherapies in Dermatologic Disorders cutaneous sarcoidosis, pemphigus, systemic vasculitides, multicentric reticulohistiocytosis, and stomatitis.…”
Section: Adalimumab (Humira)mentioning
confidence: 99%
“…Theoretically, if calibrated correctly to pharmacokinetic and pharmacodynamic equilibrium, these antagonists should allow immune system stability without causing major immunosuppression. 53 Adalimumab has been approved for the treatment of psoriatic arthritis and moderate to severe chronic psoriasis in dermatology. Case reports mention adalimumab in treating hidradenitis suppurativa, pyoderma gangrenosum, Sweet syndrome, Immunotherapies in Dermatologic Disorders cutaneous sarcoidosis, pemphigus, systemic vasculitides, multicentric reticulohistiocytosis, and stomatitis.…”
Section: Adalimumab (Humira)mentioning
confidence: 99%
“…), lymphocyte activation in the the regional lymph node with production of CD8 T lymphocytes and induction of apoptosis. 6 There are several studies on its use as an alternative therapy to LM, although they are all series or case reports with variable protocols and short followup.…”
Section: Commentsmentioning
confidence: 99%
“…24 Tem aprovação pelo FDA apenas para micose fungoide, entretanto, é utilizada para diversas doenças dermatológicas. Tem como característica principal não ser específico para nenhuma fase do ciclo celular, suprimir linfócitos B mais que os linfócitos T 25 e, entre estes, afetar mais intensamente as células T supressoras (CD8) do que as auxiliares (CD4).…”
Section: Ciclofosfamidaunclassified